Jeffrey S. Weber, MD, PhD, a senior member at Moffitt Cancer Center, discusses toxicities associated with immunotherapies for the treatment of patients with melanoma.
Jeffrey S. Weber, MD, PhD, a senior member at Moffitt Cancer Center, discusses toxicities associated with immunotherapies for the treatment of patients with melanoma.
<<<
Gertz Assesses Notable Adverse Events of Talquetamab for Relapsed/Refractory Multiple Myeloma
March 26th 2024During a Case-Based Roundtable event, Morie Gertz, MD, discussed the safety profile of talquetamab as a single agent and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
Read More
George Discusses Potency of VEGF TKIs in Advanced Renal Cell Carcinoma
March 22nd 2024During a Case-Based Roundtable® event, Saby George, MD, discussed the case of a patient with clear cell renal cell carcinoma who progressed after left nephrectomy followed by treatment with axitinib plus pembrolizumab at recurrence.
Read More